LEO Pharma has submitted an application to the European Medicines Agency (EMA) seeking to expand the label for Anzupgo (delgocitinib) cream to include adolescents aged from 12 to 17 with moderate to severe chronic hand eczema (CHE) in the European Union (EU).
The expansion is targeted at individuals for whom topical corticosteroids are not sufficient or appropriate. The European regulator has accepted the application for review.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The submission is based on outcomes from the Phase III trial, DELTA Teen, which evaluated the safety and efficacy of Anzupgo 20mg/g cream applied twice daily against a cream vehicle in this patient group.
Detailed findings from the trial were shared as a late-breaking presentation at the European Academy of Dermatology and Venereology 2025, held in Paris, France.
Research indicates that CHE in adolescents can affect more than just the skin, with significant impacts on quality of life, psychosocial health and academic performance.
The therapy is approved for use in adults with moderate to severe CHE for whom topical corticosteroids are not appropriate or sufficient in the EU, Switzerland, the US, and the UK.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLEO Pharma obtained exclusive development and commercialisation rights in 2014 for the topical use of delgocitinib in dermatological indications globally, except in Japan where Shionogi holds the rights.
LEO Pharma Development executive vice-president Sophie Lamle stated: “With the submission of our label expansion application for Anzupgo, LEO Pharma is reinforcing our commitment aiming at improving the lives of patients with skin diseases.
“Adolescents living with this debilitating disease in the EU currently have no treatment options specifically approved for moderate to severe CHE, and we are proud to take this important step toward addressing that unmet need.
“Backed by our global expertise and dedication to innovation, we are excited about the potential to bring a treatment that can help make a meaningful difference in the everyday lives of adolescent patients.”
Earlier in 2025, Gilead Sciences and LEO Pharma formed a strategic collaboration to expedite the development and commercialisation of LEO Pharma’s small molecule oral signal transducer and activator of transcription 6 programmes.
